1. Home
  2. BKU vs DMAC Comparison

BKU vs DMAC Comparison

Compare BKU & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BankUnited Inc.

BKU

BankUnited Inc.

HOLD

Current Price

$45.22

Market Cap

3.3B

Sector

Finance

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$8.45

Market Cap

441.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKU
DMAC
Founded
2009
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
441.6M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
BKU
DMAC
Price
$45.22
$8.45
Analyst Decision
Hold
Strong Buy
Analyst Count
11
4
Target Price
$42.73
$15.50
AVG Volume (30 Days)
1.0M
584.7K
Earning Date
01-21-2026
11-12-2025
Dividend Yield
2.74%
N/A
EPS Growth
44.85
N/A
EPS
3.54
N/A
Revenue
$1,016,093,000.00
N/A
Revenue This Year
$14.68
N/A
Revenue Next Year
$5.73
N/A
P/E Ratio
$12.80
N/A
Revenue Growth
10.45
N/A
52 Week Low
$28.21
$3.19
52 Week High
$46.92
$10.42

Technical Indicators

Market Signals
Indicator
BKU
DMAC
Relative Strength Index (RSI) 64.89 53.39
Support Level $45.33 $8.00
Resistance Level $46.33 $10.14
Average True Range (ATR) 0.94 0.70
MACD -0.11 -0.12
Stochastic Oscillator 44.89 25.76

Price Performance

Historical Comparison
BKU
DMAC

About BKU BankUnited Inc.

BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: